WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525060
CAS#: 189954-96-9
Description: Firocoxib is a non-steroidal anti-inflammatory drug of the COX-2 inhibitor class, currently approved for use in dogs and horses. Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses.
Hodoodo Cat#: H525060
Name: Firocoxib
CAS#: 189954-96-9
Chemical Formula: C17H20O5S
Exact Mass: 336.10
Molecular Weight: 336.400
Elemental Analysis: C, 60.70; H, 5.99; O, 23.78; S, 9.53
Synonym: ML 1,785,713; ML 1785713; ML-1,785,713; ML-1785713; ML1,785,713; ML1785713. Firocoxib; Equioxx; Previcox.
IUPAC/Chemical Name: 3-(Cyclopropylmethoxy)-4-(4-methylsulfonylphenyl)-5,5-dimethylfuranone
InChi Key: FULAPETWGIGNMT-UHFFFAOYSA-N
InChi Code: InChI=1S/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3
SMILES Code: CC1(C(=C(C(=O)O1)OCC2CC2)c3ccc(cc3)S(=O)(=O)C)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 336.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Reddyjarugu B, Pavek T, Southard T, Barry J, Singh B. Analgesic Efficacy of Firocoxib, a Selective Inhibitor of Cyclooxygenase 2, in a Mouse Model of Incisional Pain. J Am Assoc Lab Anim Sci. 2015 Jul;54(4):405-10. PubMed PMID: 26224441; PubMed Central PMCID: PMC4521575.
2: Barton MH, Darden JE, Clifton S, Vandenplas M. Effect of firocoxib on cyclooxygenase 2, microsomal prostaglandin E2 synthase 1, and cytosolic phospholipase A2 gene expression in equine mononuclear cells. Am J Vet Res. 2015 Dec;76(12):1051-7. doi: 10.2460/ajvr.76.12.1051. PubMed PMID: 26618729.
3: Stock ML, Millman ST, Barth LA, Van Engen NK, Hsu WH, Wang C, Gehring R, Parsons RL, Coetzee JF. The effects of firocoxib on cautery disbudding pain and stress responses in preweaned dairy calves. J Dairy Sci. 2015 Sep;98(9):6058-69. doi: 10.3168/jds.2014-8877. Epub 2015 Jul 2. PubMed PMID: 26142860.
4: Cancedda S, Sabattini S, Bettini G, Leone VF, Laganga P, Rossi F, Terragni R, Gnudi G, Vignoli M. Combination of radiation therapy and firocoxib for the treatment of canine nasal carcinoma. Vet Radiol Ultrasound. 2015 May-Jun;56(3):335-43. doi: 10.1111/vru.12246. Epub 2015 Feb 21. PubMed PMID: 25703137.
5: Holland B, Fogle C, Blikslager AT, Curling A, Barlow BM, Schirmer J, Davis JL. Pharmacokinetics and pharmacodynamics of three formulations of firocoxib in healthy horses. J Vet Pharmacol Ther. 2015 Jun;38(3):249-56. doi: 10.1111/jvp.12177. Epub 2014 Nov 5. PubMed PMID: 25378135.
